Esperion Therapeutics, Inc. (ESPR) Financials

ESPR Assets vs Liabilities

DateAssetsLiabilities
2023-12-31 205.8 million 660.8 million
2023-09-30 221.3 million 631.3 million
2023-06-30 234.6 million 606.6 million
2023-03-31 251.8 million 581.5 million

ESPR Free Cash Flow and Stock based compensation

Graph available only for supporters. Become a supporter to see it.
DateFree Cash FlowStock based compensation
2023-12-31 -37.1 million 2.9 million
2023-09-30 -19.3 million 3.0 million
2023-06-30 -24.8 million 3.2 million
2023-03-31 -54.4 million 2.9 million

ESPR Net Income

No data available :(

ESPR Cash and Debt

Graph available only for supporters. Become a supporter to see it.
DateCashDebtCapital Lease
2023-12-31 - - 4.6 million
2023-09-30 114.8 million - 3.0 million
2023-06-30 138.5 million 260.7 million 2.4 million
2023-03-31 162.3 million 260.3 million 1.1 million

ESPR Shares Outstanding

Graph available only for supporters. Become a supporter to see it.
DateShares Outstanding
2023-12-31 178.9 million
2023-09-30 111.9 million
2023-06-30 109.2 million
2023-03-31 78.4 million

ESPR Expenses

Graph available only for supporters. Become a supporter to see it.
DateCapexR&DG&AS&M
2023-12-31 - 17.7 million 45.4 million -
2023-09-30 - 14.9 million 33.2 million -
2023-06-30 - 22.1 million 40.7 million -
2023-03-31 - 31.4 million 41.6 million -

ESPR Cost of Revenue

Graph available only for supporters. Become a supporter to see it.
DateRevenueCost of Revenue
2023-12-31 32.3 million 11.5 million
2023-09-30 34.0 million 13.4 million
2023-06-30 25.8 million 6.8 million
2023-03-31 24.3 million 11.7 million

ESPR

Price: $2.08

52 week price:
0.70
3.40

Earnings Per Share: -2.03 USD

P/E Ratio: -1.14

Exchange: NGM

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Volume: 623424

Ebitda: -37.8 million

Market Capitalization: 465.4 million

Links: